Navigation Links
Isis Announces That OGX-011 Has Shown Overall Survival Advantage in Prostate Cancer Compared to Standard Therapy in a Randomized Phase 2 Study
Date:12/3/2008

registration trial, 20% if OGX-011 is licensed prior to marketing approval and 15% thereafter. In addition, Isis currently owns approximately 2% of the outstanding common stock of OncoGenex.

ABOUT ISIS PHARMACEUTICALS, INC.

Isis is exploiting its expertise in RNA to discover and develop novel drugs for its product pipeline and for its partners. The Company has successfully commercialized the world's first antisense drug and has 19 drugs in development. Isis' drug development programs are focused on treating cardiovascular and metabolic diseases. Isis' partners are developing antisense drugs invented by Isis to treat a wide variety of diseases. Ibis Biosciences, Inc., Isis' majority-owned subsidiary, is developing and commercializing the Ibis T5000(TM) Biosensor System, a revolutionary system to identify infectious organisms. Isis is a joint owner of Regulus Therapeutics LLC, a joint venture focused on the discovery, development and commercialization of microRNA therapeutics. As an innovator in RNA-based drug discovery and development, Isis is the owner or exclusive licensee of over 1,500 issued patents worldwide. Additional information about Isis is available at www.isispharm.com.

This press release includes forward-looking statements regarding Isis' business, its drug discovery and development pipeline, and the therapeutic potential of OGX-011 for the treatment of cancer. Any statement describing Isis' goals, expectations, financial or other projections, intentions or beliefs is a forward-looking statement and should be considered an at-risk statement, including those statements that are described as Isis' goals. Such statements are subject to certain risks and uncertainties, particularly those inherent in the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, and in the
'/>"/>

SOURCE Isis Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
4. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
5. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
6. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
7. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
8. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
9. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
10. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
11. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/18/2013)...  Decision Resources, one of the world,s leading ... issues, announces that its Market Access Tracker service ... East and Africa ... opportunities to gaining and maintaining favorable market access ... The countries covered by Market Access Tracker make ...
(Date:6/18/2013)... NEW YORK , June 18, 2013 ... Gilead Sciences, Inc. (NASDAQ: GILD ), Health Management ... (NASDAQ: IDXX ), ISIS Pharmaceuticals Inc. (NASDAQ: ... readers may access these reports free of charge - including ... the links below. Gilead Sciences, Inc. Research Report ...
(Date:6/18/2013)... 18, 2013  Pro football player and 2012 most ... family expert Jo Frost have potentially life-threatening ... the fully integrated specialty pharmaceutical business of Mylan Inc. ... this significant health problem. In recognition of the 25 ... Administration (FDA) approval of EpiPen ® (epinephrine) Auto-Injector, ...
Breaking Medicine Technology:Decision Resources' Market Access Tracker Now Covers the Middle East and Africa 2Decision Resources' Market Access Tracker Now Covers the Middle East and Africa 3Industry Shows a Healthy Pulse with Priority Reviews, Positive Results, New Testing Procedures, and Partnerships - Research Report on Gilead, Health Management, IDEXX, ISIS, and Trius Therapeutics 2Industry Shows a Healthy Pulse with Priority Reviews, Positive Results, New Testing Procedures, and Partnerships - Research Report on Gilead, Health Management, IDEXX, ISIS, and Trius Therapeutics 3Industry Shows a Healthy Pulse with Priority Reviews, Positive Results, New Testing Procedures, and Partnerships - Research Report on Gilead, Health Management, IDEXX, ISIS, and Trius Therapeutics 4Industry Shows a Healthy Pulse with Priority Reviews, Positive Results, New Testing Procedures, and Partnerships - Research Report on Gilead, Health Management, IDEXX, ISIS, and Trius Therapeutics 5Industry Shows a Healthy Pulse with Priority Reviews, Positive Results, New Testing Procedures, and Partnerships - Research Report on Gilead, Health Management, IDEXX, ISIS, and Trius Therapeutics 6Mylan Specialty L.P. Joins Forces with Adrian Peterson and Jo Frost to Launch Anaphylaxis Preparedness Campaign 2Mylan Specialty L.P. Joins Forces with Adrian Peterson and Jo Frost to Launch Anaphylaxis Preparedness Campaign 3Mylan Specialty L.P. Joins Forces with Adrian Peterson and Jo Frost to Launch Anaphylaxis Preparedness Campaign 4Mylan Specialty L.P. Joins Forces with Adrian Peterson and Jo Frost to Launch Anaphylaxis Preparedness Campaign 5Mylan Specialty L.P. Joins Forces with Adrian Peterson and Jo Frost to Launch Anaphylaxis Preparedness Campaign 6Mylan Specialty L.P. Joins Forces with Adrian Peterson and Jo Frost to Launch Anaphylaxis Preparedness Campaign 7Mylan Specialty L.P. Joins Forces with Adrian Peterson and Jo Frost to Launch Anaphylaxis Preparedness Campaign 8
(Date:6/19/2013)... Tornadoes and their devastating aftermath have increased across the ... to these deadly storms find it hard to recover. ... and corporations from natural and man-made disasters for over ... philosophy of providing a storm shelter that can be ... stand up, with light and a battery-operated blower for ...
(Date:6/19/2013)... insurance rates is a complex process that requires insurance companies ... their own company policies. This process is a big ... company, and why by shopping around for the cheapest ... car insurance can be a hefty expense for all drivers. ... that determine their car insurance premiums. These tips will ...
(Date:6/19/2013)... Transvaginal mesh lawsuits are moving along in the New Jersey ... to handle evidence in the C.R. Bard lawsuits, specifically focusing ... removed from patients. The Rottenstein Law Group LLP maintains a ... the device and a guide on how to file a ... medical facilities that currently hold them and are to maintain ...
(Date:6/19/2013)... (PRWEB) June 19, 2013 Tools4ever, a ... sponsoring today's event, at which it will be giving ... well as giving further insight into its leading-edge solutions. ... IT & business professionals specialising in IDM infrastructure and ... of markets including the public sector, banking, finance and ...
(Date:6/19/2013)... Phoenix, AZ (PRWEB) June 19, 2013 ... has been an effective answer for years, to many ... to premature hair loss and wrinkles. Essential Source® has ... Bonita V™, featuring Revytalyz 5™, that is not only ... to the vegetarian and vegan community. , ...
Breaking Medicine News(10 mins):Health News:Radius Engineering International Inc. Tornado-Resistant Storm Shelters 2Health News:icandrive.ca Provides Tips to Understand the Top Factors That Affect Car Insurance Premiums 2Health News:icandrive.ca Provides Tips to Understand the Top Factors That Affect Car Insurance Premiums 3Health News:Transvaginal Mesh Lawsuit News: NJ Mesh Consolidation Cases Moving Along, Rottenstein Law Group LLP Reports 2Health News:Essential Source ® Improves On Best Selling Bonita ™ Hair Skin and Nail Product 2
... researchers, physicians, technologists and medical experts from across ... to explore topics in nuclear medicine, molecular imaging, ... Mid-Winter Meetings. , Four meetings were held ... Educational Symposium of the American College of Nuclear ...
... NEW YORK , Feb. 9 As part ... development of life-transforming treatments and a cure for Parkinson,s disease, ... in total funding for seven research projects aiming to push ... therapeutic development. , While new genetic and cellular targets ...
... Feb. 9 Chiquita Brands International, Inc. (NYSE: ... Fresh Produce Association Foundation,s " A Salad Bar in Every ... health commitment by Chiquita and its Fresh Express subsidiary will ... across America.  Chiquita is the first produce company to commit ...
... clinical data for nearly 800 patients with non-small cell lung ... with age and sex specific patterns of increased or decreased ... issue of JAMA . The five-year overall survival ... remains the leading cause of cancer-related death in the United ...
... People with cystic fibrosis, an inherited disease that clogs ... defy treatment. While the life expectancy for children with ... many lives are still shortened in young adulthood by ... are often caused by common, environmental microbes that mutate ...
... First Lady Michelle ... number of chronic diseases including diabetes, heart disease, osteoarthritis, and sleep apnea. ... Washington, DC (Vocus) February 9, ... a risk factor for a number of chronic diseases including diabetes, heart disease, osteoarthritis, and ...
Cached Medicine News:Health News:SNM's Conjoint Mid-Winter Meetings continue to advance molecular imaging 2Health News:SNM's Conjoint Mid-Winter Meetings continue to advance molecular imaging 3Health News:Michael J. Fox Foundation Awards $1 Million to Drive Critical New Research Tools and Technologies in Parkinson's Drug Development 2Health News:Michael J. Fox Foundation Awards $1 Million to Drive Critical New Research Tools and Technologies in Parkinson's Drug Development 3Health News:Michael J. Fox Foundation Awards $1 Million to Drive Critical New Research Tools and Technologies in Parkinson's Drug Development 4Health News:Chiquita Announces Support for School Salad Bar Campaign 2Health News:Chiquita Announces Support for School Salad Bar Campaign 3Health News:Certain genetic profiles associated with recurrence-free survival for non-small cell lung cancer 2Health News:Certain genetic profiles associated with recurrence-free survival for non-small cell lung cancer 3Health News:Adapting to clogged airways makes common pathogen resist powerful drugs 2Health News:Adapting to clogged airways makes common pathogen resist powerful drugs 3Health News:National Wildlife Federation Says Outdoor Time for Kids Can Help First Lady Achieve Her “Let's Move” Goal 2Health News:National Wildlife Federation Says Outdoor Time for Kids Can Help First Lady Achieve Her “Let's Move” Goal 3
Smart Cryo is a powerful cool-air generator that provides intense localised skin cooling without any contact, thus guaranteeing a high degree of hygiene and an effective cooling action, indispensable...
... is an exceptional condensate of ... dimensions for ensuring a rational ... constantly evolving professional market. PhotoLight ... in different studios who require ...
... is a CO2 laser system with CW ... for dealing with all therapeutic application in ... supplies medium-to-high intensities in super-pulsed mode, designed ... surgery. It is also capable of supplying ...
... HIPAA-secure web-based access to patient document 24 ... through the utilization of TrackDoc. Healthcare ... the original dictation at the same time, ... document, and fax to referring physicians or ...
Medicine Products: